Susmed

Susmed Current Liabilities

The Current Liabilities of Susmed (4263.T) as of Oct 29, 2026 is 99.96 M JPY. In the previous year, Current Liabilities was 101.77 M JPY — a change of -1.78% (lower).

Current Liabilities

99.96 MJPY

YoY

-1.78%

Last updated:

Current Liabilities of Susmed is 2026 99.96 M JPY. Current Liabilities of Susmed was 2025 101.77 M JPY. It decreases by -1.78% lower compared to the previous year.

The Susmed Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2020
-2.78 M JPY
Jan 1, 2021
2.91 M JPY
Jan 1, 2022
52.09 M JPY
Jan 1, 2023
98.19 M JPY
Jan 1, 2024
84.17 M JPY
Jan 1, 2025
101.77 M JPY
Jan 1, 2026
99.96 M JPY
The Susmed Current Liabilities history
YEARCurrent LiabilitiesYoY
99.96 MJPY-1.78%
101.77 MJPY+20.92%
84.17 MJPY-14.28%
98.19 MJPY+88.52%
52.09 MJPY+1,691.74%
2.91 MJPY-204.46%
-2.78 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Susmed Stock analysis

What does Susmed do? SUSMED, Inc. generates revenue through its DTx Product segment, which develops application software for treating insomnia, breast cancer, and chronic kidney diseases. The DTx Platform segment provides clinical trial systems, machine learning analysis systems, and DTx development support services. The company's primary customers are healthcare providers and pharmaceutical companies seeking digital therapeutics solutions. SUSMED targets the healthcare technology market with its specialized software and support services for disease treatment and clinical research. The DTx Product segment focuses on creating therapeutic applications for specific medical conditions, while the DTx Platform segment offers infrastructure for clinical trials and machine learning analysis. SUSMED's business model relies on selling both its proprietary software products and platform services to healthcare institutions and pharmaceutical firms. The company's revenue streams include software licensing, system subscriptions, and development support fees. SUSMED's products are designed to address chronic conditions like insomnia and breast cancer, with additional focus on chronic kidney diseases. The DTx Platform serves as a comprehensive solution for clinical trial management and machine learning-driven analysis, supporting pharmaceutical companies in their drug development processes. The company's services are tailored to meet the needs of healthcare technology providers and pharmaceutical developers. Susmed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Susmed stock

Current Liabilities of Susmed is 99.96 M JPY in 2026.

Current Liabilities of Susmed changed from 101.77 M JPY to 99.96 M JPY, representing a -1.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Susmed since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Susmed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Susmed

All Key Metrics — Susmed